SCHEMBL7991895

SCHEMBL7991895

CC(O)Cn1cccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11016362 0.76 KDM4E (0.38)
SCHEMBL7350683 0.74 TSHR (0.35)
SCHEMBL6627458 0.74 SLC18A3 (0.37)
SCHEMBL536767 0.72
SCHEMBL537360 0.72
SCHEMBL536783 0.72
SCHEMBL28124381 0.72 KDM4E (0.30)
SCHEMBL7647881 0.72
SCHEMBL25661035 0.70 CYP1A2 (0.43)
SCHEMBL7126010 0.70 KDM4E (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570645-B2 Uses of p53 x-ray co-crystal structures PMV PHARMACEUTICALS, INC. (US) 2026-03-10 US disclosed
US-20260027097-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-01-29 US disclosed
US-12419880-B2 Companion diagnostic tool for mutant p53 reactivating compounds PMV PHARMACEUTICALS, INC. (US) 2025-09-23 US disclosed
US-20240269126-A1 COMBINATION THERAPY FOR TREATMENT OF CANCER PMV PHARMACEUTICALS, INC. 2024-08-15 US disclosed
US-11938124-B2 Combination therapy for treatment of cancer PMV PHARMACEUTICALS, INC. (US) 2024-03-26 US disclosed
US-20230049952-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 US disclosed
US-20230044826-A1 COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS PMV PHARMACEUTICALS, INC. 2023-02-09 US disclosed
US-20230033324-A1 COMBINATION THERAPY FOR TREATMENT OF CANCER PMV PHARMACEUTICALS, INC. 2023-02-02 US disclosed
US-20230024905-A1 USES OF P53 X-RAY CO-CRYSTAL STRUCTURES PMV PHARMACEUTICALS, INC. 2023-01-26 US disclosed
EP-3679034-A1 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION Immunic AG (DE) 2020-07-15 EP disclosed
EP-2711383-B1 CATALYST SOLUTION FOR USE IN PRODUCTION OF POLYESTER, AND METHOD FOR PRODUCING POLYESTER RESIN USING SAME TORAY INDUSTRIES (JP) 2018-07-04 EP disclosed
CN-104059073-B Imidazopyrizine Syk Inhibitors 吉利德康涅狄格公司 2017-04-12 CN disclosed
CN-105727828-A Cationic gemini surfactants and preparation method thereof 江南大学 2016-07-06 CN disclosed
CN-103534291-B Catalyst solution for use in production of polyester, and method for producing polyester resin using same TORAY INDUSTRIES 2015-06-24 CN disclosed
US-20150045530-A1 CATALYST SOLUTION FOR USE IN PRODUCTION OF POLYESTER, AND METHOD FOR PRODUCING POLYESTER RESIN USING SAME TORAY INDUSTRIES, INC. (JP) 2015-02-12 US disclosed
EP-2711383-A1 CATALYST SOLUTION FOR USE IN PRODUCTION OF POLYESTER, AND METHOD FOR PRODUCING POLYESTER RESIN USING SAME Toray Industries, Inc. (JP) 2014-03-26 EP disclosed
CN-103534291-A Catalyst solution for use in production of polyester, and method for producing polyester resin using same TORAY INDUSTRIES 2014-01-22 CN disclosed
US-6291596-B1 CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT JSR CORPORATION (JP) 2001-09-18 US disclosed
EP-0974602-A1 Catalyst and process for hydrogenating olefinically unsaturated compound JSR Corporation (JP) 2000-01-26 EP disclosed
US-4336061-A Herbicidal azolyl chloroacetanilides, compositions and method of use BASF AKTIENGESELLSCHAFT (DE) 1982-06-22 US disclosed